Rezolute, Inc. Common Stock (NV) (RZLT) Stock
NASDAQ · RZLT
Key stats
- Market cap
- $393.69M
- Price / Earnings ratio
- -5.0x
- EPS (TTM)
- -$0.76
- Volume
- Loading
- 52-week high
- $11.17
- 52-week low
- $1.07
Source: third-party data provider, as of November 13, 2026
Compare with RZLT
Recent news

Zacks Investment Research
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
RZLTJune 4, 2026
Zacks Investment Research
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
RZLT

Zacks Investment Research
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLTMarch 25, 2026
Zacks Investment Research
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT

Business Wire
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute
RZLTMarch 6, 2026
Business Wire
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute
RZLT

Zacks Investment Research
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
RZLTDecember 17, 2025
Zacks Investment Research
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
RZLT
Technical indicators
- RSI 14
- 51.48
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.08
- MACD histogram
- 0.02
- SMA 50
- $4.10
- Price below SMA 50
- EMA 50
- $4.13
- Price below EMA 50
- SMA 200
- $3.92
- Price above SMA 200
- EMA 200
- $4.18
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Strong Sell0
Sell0
Hold0
Buy5
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2022
2023
2024
2025
2026
0000
Debt & Balance Sheet
Total assets
Total liabilities
2022
2023
2024
2025
2026
211M139M69M0
Revenue to Profit
2026$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-77.6M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
RZLTJune 4, 2026
Zacks Investment Research
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
RZLT

Zacks Investment Research
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLTMarch 25, 2026
Zacks Investment Research
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT

Business Wire
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute
RZLTMarch 6, 2026
Business Wire
RZLT INVESTOR ALERT: Faruqi & Faruqi, LLP Launches Investigation into Rezolute
RZLT

Zacks Investment Research
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
RZLTDecember 17, 2025
Zacks Investment Research
RZLT Stock Plummets 79% Month to Date: Here's What You Need to Know
RZLT

Stocktwits
RZLT Stock Lost Nearly 90% Of Its Value Today – What Did The Company’s Latest Trial Reveal?
RZLTDecember 11, 2025
Stocktwits
RZLT Stock Lost Nearly 90% Of Its Value Today – What Did The Company’s Latest Trial Reveal?
RZLT
About Rezolute, Inc. Common Stock (NV)
No description available.
SectorHealthcare
IndustryBiotechnology
Employees58
CEOMr. Nevan Charles Elam J.D.
IPO DateMay 1, 2014
HeadquartersRedwood City, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Nevan Charles Elam J.D. | Founder, CEO & Acting Chairman of the Board | 1967 |
| Mr. Daron G. Evans M.B.A., M.S. | Chief Financial & Business Officer | 1974 |
| Dr. Brian Kenneth Roberts M.D. | Chief Medical Officer | 1975 |
| Mr. Michael R. Deperro | Senior VP & Head of Operations | — |
| Dr. Davelyn Eaves Hood M.B.A., M.D. | Director and Head of Scientific & Patient Affairs | — |
| Ms. Melissa Quinn | Senior Director of People and Culture | — |
Fundamentals
Valuation
Price-to-book value4.52
Profitability
Return on Equity-63.00%
Return on Assets-58.00%
EBITDA$-76.98M
Trading
Average volume1,353,488
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.48
- MACD 12/26/9
- -0.06
- EMA 9 of MACD
- -0.08
- MACD histogram
- 0.02
- SMA 50
- $4.10
- Price below SMA 50
- EMA 50
- $4.13
- Price below EMA 50
- SMA 200
- $3.92
- Price above SMA 200
- EMA 200
- $4.18
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $7.00
- Average
- $11.00
- High
- $15.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -18.1 | +2.8 | ||||||||||
| 2022 | -10.6 | -45.2 | +25.7 | +5.0 | -27.3 | +14.1 | -10.3 | -23.5 | +18.6 | -38.3 | -0.6 | +27.8 |
| 2023 | +36.7 | -10.5 | -24.7 | +2.0 | +1.4 | +0.5 | -7.9 | -18.6 | -9.6 | -23.4 | -25.2 | +22.2 |
| 2024 | +7.8 | +66.7 | +41.7 | +10.7 | +46.0 | +4.6 | +6.7 | +7.9 | +3.2 | +19.4 | -8.4 | -3.9 |
| 2025 | +1.9 | -15.5 | -30.0 | +28.8 | +4.0 | +5.4 | +34.6 | +21.3 | +31.1 | -1.2 | +6.8 | -74.3 |
| 2026 | +53.9 | -0.9 | -2.9 | +2.2 | +0.0 | +44.0 | -4.6 | -4.5 | -8.0 | -2.9 | +4.9 |
Compare stocks
Market cap
$393.69M
-
-
-
Price / Earnings ratio
-5.00
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
1,353,488
-
-
-
Earnings per share
$-0.76
-
-
-



